Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.67 |
| ▸ | AGXT | P21549 | 2/20 | 0.67 |
| ▸ | MAOB | P27338 | 7/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31264 | 0.83 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL3768643 | 0.83 | IDO1 (0.71) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL3156159 | 0.81 | IDO1 (0.62) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL1520782 | 0.80 | IDO1 (1.00) | IDO1AGXTMAOBTAAR1 | |
| SCHEMBL3389080 | 0.80 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL5315445 | 0.80 | TAAR1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL27886344 | 0.80 | IDO1 (0.67) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL2091873 | 0.79 | IDO1 (0.61) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL96112 | 0.79 | TAAR1 (0.60) | IDO1AGXTMAOBTAAR1CHRM2 | |
| SCHEMBL723511 | 0.79 | TAAR1 (0.77) | IDO1AGXTTAAR1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | disclosed |
| EP-3864032-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi iPSUM S.r.l. (IT) | 2021-08-18 | — | — | EP | disclosed |
| CN-112912390-A | Preparation method of GLP-1 analogue | 费森尤斯卡比有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2805948-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | Santen Pharmaceutical Co., Ltd (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| WO-2004108661-A1 | AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS (US) | 2004-12-16 | — | — | WO | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-4195178-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4181798-A | Methylenecyclopentane derivatives | THE UPJOHN COMPANY (US) | 1980-01-01 | — | — | US | disclosed |
| US-4175202-A | 4,5,6-Trinor-3,7,-inter-m-phenylene prostaglandin A1 analogs | THE UPJOHN COMPANY (US) | 1979-11-20 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4084058-A | HYPOTENSIVES, ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | IDO1 2152/4885AGXT 1488/4885MAOB 1941/4885 |
| US-20140371459-A1 | INDUSTRIAL PROCESS FOR PREPARATION OF 1,2-DIHYDROQUINOLINE DERIVATIVE OR A SALT THEREOF, AND INTERMEDIATE FOR PREPARATION THEREOF | NR3C2, NR5A1, NR3C1 | IDO1 2632/4885AGXT 3600/4885MAOB 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.